Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05464082). This is a study registration, not published results. Lead sponsor: University of Utah. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 80 participants (ESTIMATED). Conditions: Breast Cancer Recurrent. Interventions: OTHER: Functional Precision Oncology. Primary outcome measures: Proportion of cases where clinically actionable therapies were identified by FPO. , up to 3 years; Compare the distant recurrence rates between patients whose tumors successfully engrafted in mice (PDX+) vs. not (PDX-) , Data will be assessed at 1-year and 3-year endpoints from the time of definitive surgery.; Compare the recurrence rates between patients whose tumors successfully engrafted in mice (PDX+) vs. not (PDX-) , Data will be assessed at 3-years from the time of definitive surgery.. Brief summary: This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.